Results 41 to 50 of about 3,871 (249)

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son, Inyoung Hwang, Sang Won Lee, Yun Kim   +3 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Management of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

Jurnal Penyakit Dalam Indonesia, 2021
Chronic kidney disease (CKD) is still a burden on worldwide health issues affecting about 11-13% of the general population. Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a common complication in CKD, which occurs early in the disease, and
Pringgodigdo Nugroho
doaj   +1 more source

Bone Disorders in Pediatric Chronic Kidney Disease: A Literature Review

Biology, 2023
Intense changes in mineral and bone metabolism are frequent in chronic kidney disease (CKD) and represent an important cause of morbidity and reduced quality of life. These disorders have conventionally been defined as renal osteodystrophy and classified
Lavinia Capossela, Serena Ferretti, Silvia D’Alonzo, Lorenzo Di Sarno, Valeria Pansini, Antonietta Curatola, Antonio Chiaretti, Antonio Gatto   +7 more
doaj   +1 more source

The Role of Bone Biopsy in the Management of CKD-MBD

Calcified Tissue International, 2021
A bone biopsy is still considered the gold standard for diagnosis of renal osteodystrophy. It allows to measure both static and dynamic parameters of bone remodeling and is the only method able to evaluate mineralization and allows analysis of both cortical and trabecular bone.
Ana Carina Ferreira, Martine Cohen-Solal, Patrick C. D’Haese, Aníbal Ferreira   +3 more
openaire   +4 more sources

Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis

Arthritis Care &Research, EarlyView.
Objective Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort.
Shangzhu Zhang, Laurence Magder, Daniel Goldman, Judith A. James, Joel M. Guthridge, Carla Guthridge, Peter Izmirly, Jill P. Buyon, H. Michael Belmont, Richard A. Furie, Noa Schwartz, Chaim Putterman, Jennifer L. Barnas, Jennifer H. Anolik, Sarah French, Maria Dall'Era, Avi Z. Rosenberg, Jeffrey Hodgin, Dawit S. Demeke, the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) Network, Michelle Petri, Andrea Fava   +21 more
wiley   +1 more source

Optimizing Hydroxychloroquine Blood Levels and Long‐Term Hydroxychloroquine Intake Could Lower Atherosclerotic Cardiovascular Disease Risk and Prevent Polypharmacy in Systemic Lupus Erythematosus

Arthritis Care &Research, EarlyView.
Objective Hydroxychloroquine (HCQ) is the cornerstone of systemic lupus erythematosus (SLE) management with benefits extending beyond SLE control, including protection against atherosclerotic cardiovascular disease (ASCVD). Although HCQ blood levels reflect recent exposure and long‐term intake reflects medication adherence, the impact of longitudinal ...
Shivani Garg, Murray Urowitz, Charlie Dentz, Niriti Adhikari, Fauzia Hollnagel, Nathalie Costedoat‐Chalumeau   +5 more
wiley   +1 more source

Elevated Liver Enzymes Is Not an Impediment to Allopurinol Dose Escalation: An Observational Cohort Study

Arthritis Care &Research, EarlyView.
Objective Routine liver enzyme monitoring is advocated for while on allopurinol, but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzyme levels in patients with gout commenced on allopurinol. Methods One hundred and fifty patients with gout and normal baseline serum aminotransferases initiated on ...
May Shuen Tang, Qai Ven Yap, Peter Pak Moon Cheung, Amelia Santosa, Gim Gee Teng   +4 more
wiley   +1 more source

Real‐World Safety of Concomitant Colchicine and Statin Therapy

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the risk of clinically meaningful muscle‐ and liver‐related outcomes associated with concomitant colchicine–statin therapy in a real‐world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
Roni Meidan, Ranel Loutati, Dan Caspi, Ori Elkayam, Ran Abuhasira, Tali Eviatar   +5 more
wiley   +1 more source

Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)

Scientific Reports
Chronic kidney disease-mineral and bone disorder (CKD-MBD) are recognized as a systemic disease affecting the prognosis of patients with CKD. Proper management of CKD-MBD is important to improve the prognosis of patients with CKD. Although proteinuria is
Sho Shimamoto, Takako Nakahara, Shunsuke Yamada, Hajime Nagasu, Seiji Kishi, Naoki Nakashima, Kazuhiko Tsuruya, Hirokazu Okada, Kouichi Tamura, Ichiei Narita, Shoichi Maruyama, Yuichiro Yano, Takashi Yokoo, Takashi Wada, Jun Wada, Eiichiro Kanda, Hiromi Kataoka, Masaomi Nangaku, Naoki Kashihara, Toshiaki Nakano   +19 more
doaj   +1 more source